Mode
Text Size
Log in / Sign up
N/A N=1,089

Survey on PD Patients With Depressive Symptoms

Parkinson Disease

Enrolled (actual)
1,089
Serious AEs
2.5%
Results posted
Jul 2011
Primary outcome: Primary: Percentage of Participants With Adverse Events, Adverse Drug Reactions, and Serious Adverse Events — 21.7; 19.2; 2.5 percentage of participants

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Age
Adult, Older Adult · 20+ yrs
Sex
All
Sponsor
Boehringer Ingelheim
Primary completion
Aug 2009

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Participants With Adverse Events, Adverse Drug Reactions, and Serious Adverse Events
21.7; 19.2; 2.5
SECONDARY
Clinical Global Impression of Improvement
76; 399; 348; 102; 24
SECONDARY
Mean Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Total Score
-7.2 <0.0001 sig
SECONDARY
Mean Change From Baseline in Beck's Depression Inventory (BDI) Total Score
-4.8 <0.0001 sig
SECONDARY
Mean Change From Baseline in UPDRS (Unified Parkinson's Disease Rating Scale) Part I Item 3 Score
-0.7 <0.0001 sig
SECONDARY
Mean Change From Baseline in Modified Hoehn & Yahr Rating Scale
-0.3 <0.0001 sig

Summary

The primary objective of this investigation is to conduct a 12-week prospective survey in PD patients with depressive symptoms treated with BI Sifrol Tablets (hereinafter referred to as this drug) in the routine clinical settings to determine the following items related to the safety and efficacy. i. Adverse drug reaction symptoms, incidence, and severity ii. Motor capacity during the investigation iii. Depressive symptoms during the investigation

Eligibility Criteria

Inclusion criteria

**PD patients with depressive symptoms Patients who have not received pramipexole hydrochloride hydrate preparations within 1 month before survey entrance.

Exclusion criteria

  • PD patients with the past history of suicidal attempt, suicidal ideation or tendency
  • PD patients with suicidal ideation
  • PD patients with the past history of suicidal tendency
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00614575). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search